

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/498,046
		Filing Date	February 4, 2000
		First Named Inventor	Sabine Neirynck
		Prior Art Unit	1648
		Examiner Name	Stacy Brown Chen
Sheet 1 of 3	Attorney Docket Number	VIB-103.0 (1796/97843)	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	E1	5,871,747	2-16-1999	Gengoux-Sedlik et al. (English)	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	E2	WO 94/06472	31 March 1994	Gengoux et al.-(Femish)		
	E3	AU 49273 90	09 Aug 1990	Highfield et al.		
	E4	WO 98/23735	04 June 1998	Mizzen et al.		

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	E5	Opposition Letter dated Sept. 4, 2006 to European Patent No. EP 0 996 717 B1	
	E6	Notice of Opposition to European Patent No. EP 0 996 717 B1 dated Sept. 5, 2006	
	E7	Opposition Letter dated Sept. 5, 2006 to European Patent No. EP 0 996 717 B1	
	E8	Opposition Letter dated Sept. 7, 2006 to European Patent No. EP 0 996 717 B1	
	E9	Slepushkin et al., Vaccine, Vol. 13, No. 15, pp 1399-1402, 1995 "Protection of Mice Against Influenza a Virus Challenge by Vaccination with Baculovirus-Expressed M2 Protein"	
	E10	Pouwels et al., Journal of Biotechnology 44 (1996) 183-192 "The Potential of Lactobacillus as a Carrier for Oral Immunization: Development and Preliminary Characterization of Vector Systems for Targeted Delivery of Antigens"	
	E11A	(English version) Insertie Van Nucleoproteïne T-Cel Epitope Van Het Influenza A Virus in Het M2-Hepatitis B Core Fusie-Eiwit, by Bart Bamps, Promotor: Professor Willy Min Jou, Begeleider: Sabine Neirynck, Laboratorium voor Moleculaire Biologie VIB, Universiteit GENT, Academiejear 1996-1997, Academic Degree obtained July 2, 1997	
	E11B	(Femish version) Insertie Van Nucleoproteïne T-Cel Epitope Van Het Influenza A Virus in Het M2-Hepatitis B Core Fusie-Eiwit, by Bart Bamps, Promotor: Professor Willy Min Jou, Begeleider: Sabine Neirynck, Laboratorium voor Moleculaire Biologie VIB, Universiteit GENT, Academiejear 1996-1997, Academic Degree obtained July 2, 1997	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/498,046
			Filing Date	February 4, 2000
			First Named Inventor	Sabine Neirynck
			Prior Art Unit	1648
			Examiner Name	Stacy Brown Chen
Sheet 2 of 3	Attorney Docket Number		VIB-103.0 (1796/97843)	

E12A	(English version) Een Expressieplasmide Leidend Tot De Presentatie Van Influenza M2 Eiwitepitopen Op Het E. Coli Celoppervlak, by Sabine Neirynck, Promotor: Professor W. Fiers, Laboratorium voor Moleculaire Biologie VIB, Rijksuniversiteit GENT, Academiejear 1987-1988, Academic Degree obtained September 30, 1988
E12B	(Femish version) Een Expressieplasmide Leidend Tot De Presentatie Van Influenza M2 Eiwitepitopen Op Het E. Coli Celoppervlak, by Sabine Neirynck, Promotor: Professor W. Fiers, Laboratorium voor Moleculaire Biologie VIB, Rijksuniversiteit GENT, Academiejear 1987-1988, Academic Degree obtained September 30, 1988
E13	Lamb, R.A. <i>et al.</i> , "Influenza Virus M ₂ Protein is an Integral Membrane Protein Expressed on the Infected-Cell Surface," <i>Cell</i> 40:627-633 (1985);
E14	Charbit, A., <i>et al.</i> , "Probing the Topology of a Bacterial Membrane Protein by Genetic Insertion of a Foreign Epitope; Expression at the Cell Surface," <i>EMBO J.</i> 5:3029-3037 (1986)
E15	Charbit, A., <i>et al.</i> , Presentation of Two Epitopes of the preS2 Region of Hepatitis B Virus on Live Recombinant Bacteria, " <i>J. Immunol.</i> , 139:1658-1664 (1987);
E16	Francis, M.J., <i>et al.</i> , "Peptide Vaccines Based on Enhanced Immunogenicity of Peptide Epitopes Presented with T-Cell Determinants or Hepatitis B Core Protein," In: Antibodies, Antigens, and Molecular Mimicry, Methods in Enzymology Vol. 178, J.J. Lagone, editor, pages 659-676, Academic Press, Inc., New York (1989)
E17	Borisova, G.P., <i>et al.</i> , "Recombinant Core Particles of Hepatitis B Virus Exposing Foreign Antigenic Determinants on Their Surface," <i>FEBS Letters</i> 259: 121-124 (1989);
E18	Clarke, B.E., <i>et al.</i> , "Presentation and Immunogenicity of Viral Epitopes on the Surface of a Hybrid Hepatitis B Virus Core Particles Produced in Bacteria," <i>J. General Virology</i> 71: 1109-1117 (1990);
E19	Francis, M.J., <i>et al.</i> , "Immunological Properties of Hepatitis B Core Antigen Fusion Proteins," <i>Proc. Natl. Acad. Sci.</i> 87:2545-2549 (1990);
E20	Clarke, B.E., <i>et al.</i> , "Improved Immunogenicity of a Peptide Epitope After Fusion to Hepatitis B Core Protein," <i>Nature</i> 330:381-384 (1987);
E21	Brown, A.L., <i>et al.</i> , "Foreign Epitopes in Immunodominant Regions of Hepatitis B Core Particles are Highly Immunogenic and Conformationally Restricted," <i>Vaccine</i> 9:595-601 (1991);
E22	von Brunn, A., <i>et al.</i> , "Principal Neutralizing Domain of HIV-1 is Highly Immunogenic when Expressed on the Surface of Hepatitis B Core Particles," <i>Vaccine</i> 11:817-824 (1993);
E23	Pumpens, P., <i>et al.</i> , "Hepatitis B Virus Core Particles as Epitope Carriers," <i>Intervirology</i> 38:63-74 (1995);
E24	Zebedee, S.L., <i>et al.</i> , "Characterization of the Influenza Virus M2 Integral Membrane Protein and Expression at the Infected-Cell Surface from Cloned cDNA," <i>J. Virology</i> 56:502-511 (1985);
E25	Zebedee, S.L., <i>et al.</i> , "Influenza A Virus M2 Protein: Monoclonal Antibody Restriction of Virus Growth and Detection of M2 in Virions," <i>J. Virology</i> 62(8):2762-2772 (1988);
E26	Katz, J.M., <i>et al.</i> , "Immune Mechanisms of Protection Induced by Vaccination of BALB/c Mice with Influenza A Virus M2 Protein," In: <i>Options for the Control of Influenza III</i> , Leo Brown, <i>et al.</i> (eds.), pages 837-843 Elsevier, B.V., (1996)
E27	Slepishkin, V.A., <i>et al.</i> , "Protection of Mice Against Influenza A Virus Challenge by Vaccination with Baculovirus-Expressed M2 Protein," <i>Vaccine</i> 13:1399-1402 (1995).
E28	Treanor, J.J. <i>et al.</i> , "Passively Transferred Monoclonal Antibody to the M2 Protein Inhibits Influenza A Virus Replication in Mice," <i>Journal of Virology</i> , 64(3):1375-1377 (1990)
E29	Black, R.A. <i>et al.</i> , "Antibody Response to the M2 Protein of Influenza A Virus Expressed in Insect Cells", <i>Journal of General Virology</i> 74:143-146 (1993)
E30	Hongo, S. <i>et al.</i> , "Characterization of a Second Protein (CM2) Encoded by RNA Segment 6 of Influenza C Virus", <i>Journal of Virology</i> 71(4):2786-2792 (Apr. 1997)
E31	Milich, D.R. <i>et al.</i> , "The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety", <i>An NY Acad Sci.</i> 754: 187-201 (1995)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/498,046
				Filing Date	February 4, 2000
				First Named Inventor	Sabine Neirynck
				Prior Art Unit	1648
				Examiner Name	Stacy Brown Chen
Sheet	3	of	3	Attorney Docket Number	VIB-103.0 (1796/97843)

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**